Regina W Hofland
Overview
Explore the profile of Regina W Hofland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Niewold P, Dijkstra D, Cai Y, Goletti D, Palmieri F, van Meijgaarden K, et al.
Sci Rep
. 2023 Jul;
13(1):11617.
PMID: 37464009
Tuberculosis (TB) is a prevalent disease causing an estimated 1.6 million deaths and 10.6 million new cases annually. Discriminating TB disease from differential diagnoses can be complex, particularly in the...
2.
Aalbers B, Mohamed Hoesein F, Hofland R, Bronsveld I, Kruijswijk M, Schotman S, et al.
Pediatr Pulmonol
. 2023 May;
58(8):2317-2322.
PMID: 37222401
Introduction: A triple combination of CFTR modulators ELE/TEZ/IVA (elexacaftor/tezacaftor/ivacaftor, Trikafta™) has been evaluated in clinical trials for people with cystic fibrosis (pwCF) and was approved to the European and US...
3.
Delemarre E, van Hoorn L, Bossink A, Drylewicz J, Joosten S, Ottenhoff T, et al.
Front Immunol
. 2021 Oct;
12:725447.
PMID: 34691031
Introduction: There is an urgent medical need to differentiate active tuberculosis (ATB) from latent tuberculosis infection (LTBI) and prevent undertreatment and overtreatment. The aim of this study was to identify...
4.
Aalbers B, Bronsveld I, Hofland R, Heijerman H
J Pers Med
. 2021 Aug;
11(8).
PMID: 34442455
Highly effective CFTR modulators such as elexacaftor/tezacaftor/ivacaftor (ELE/TEZ/IVA will become available for an increasing number of people with cystic fibrosis (pwCF) in the near future. Before the start of this...
5.
Bok J, Hofland R, Evans C
Front Immunol
. 2021 May;
12:641082.
PMID: 34046032
Background: Whole blood mycobacterial growth assays (WBMGA) quantify mycobacterial growth in fresh blood samples and may have potential for assessing tuberculosis vaccines and identifying individuals at risk of tuberculosis. We...
6.
Hofland R, Bossink A, Nierkens S, Paardekooper S, van den Broek B, Lammers J, et al.
Infect Dis (Lond)
. 2018 Jan;
50(6):479-482.
PMID: 29334817
No abstract available.
7.
Hofland R, Thijsen S, van Lindert A, de Lange W, van Gorkom T, van der Tweel I, et al.
Infect Dis (Lond)
. 2016 Dec;
49(5):347-355.
PMID: 28024452
Background: The aim of this study was to evaluate the positive predictive value (PPV) of ELISpot in bronchoalveolar lavage (BAL) and pleural fluid for the diagnosis of active tuberculosis (TB)...
8.
Hofland R, Bossink A, Lammers J, Thijsen S
J Clin Microbiol
. 2016 Jan;
54(2):504-5.
PMID: 26822769
No abstract available.
9.
Hofland R, Thijsen S, Bouwman J, van der Wel M, Bossink A
Sarcoidosis Vasc Diffuse Lung Dis
. 2014 Aug;
31(2):142-8.
PMID: 25078642
Background: The possible association between (tuberculous and nontuberculous) mycobacterial infections and sarcoidosis is still a matter of dispute. Using diagnostic tests for specific T-cell responses, this association can be investigated...
10.
Hofland R, Thijsen S, Verhagen M, Schenk Y, Bossink A
Thorax
. 2013 Apr;
68(11):1079-80.
PMID: 23598710
As part of a prospective study on the safety of TNF-α inhibitor therapy after screening for and treatment of latent tuberculosis infection (LTBI), we report two patients who developed active...